Print

Santarus Inc. (SNTS) Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea  
10/4/2013 6:58:21 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Santarus, Inc. (NASDAQ:SNTS) today announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX® in patients with travelers’ diarrhea will be featured in a poster presentation at IDWeek™ in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m. to 2:00 p.m. Pacific Time on Saturday, October 5, 2013. Help employers find you! Check out all the jobs and post your resume.

//-->